UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

 

IN8bio, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 Par Value Per Share

(Title of Class of Securities)

 

45674E 109

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b) 

 

¨ Rule 13d-1(c) 

 

x Rule 13d-1(d) 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 45674E 109 Page 2 of 4 Pages

 

1.

Name of Reporting Persons

William Tai-Wei Ho

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨ (b) ¨

3. SEC USE ONLY
4.

Citizenship or Place of Organization

United States of America

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

  5.

Sole Voting Power

2,871,006(1)

  6.

Shared Voting Power

255,499(2)

  7.

Sole Dispositive Power

2,871,006(1)

  8.

Shared Dispositive Power

145,999(3)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

3,126,505(1)(2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

¨

11.

Percent of Class Represented by Amount in Row (9)

7.1%(4)

12.

Type of Reporting Person (See Instructions)

IN

 

(1)  Consists of (i) 2,421,512 shares of Common Stock held of record by the Reporting Person and (ii) 449,494 shares of Common Stock underlying outstanding options held by the Reporting Person that are immediately exercisable or will be immediately exercisable within 60 days of December 31, 2023.

(2)  Consists of (i) 145,999 shares of Common Stock held of record by the Reporting Person’s two minor children and (ii) 109,500 shares of Common Stock held of record by certain other relatives of the Reporting Person, over which, under all but certain limited circumstances, the Reporting Person holds an irrevocable proxy, pursuant to voting agreements between the Reporting Person, the Issuer, and such stockholders.

(3) Consists of 145,999 shares of Common Stock held of record by the Reporting Person’s two minor children.

(4) The calculation is based on dividing (a) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 43,287,325 shares of Common Stock outstanding as of as of January 1, 2024 as reported by the Issuer on its Prospectus, dated and filed with the Securities and Exchange Commission on January 18, 2024, and (ii) 449,494 shares of Common Stock underlying outstanding options held by the Reporting Person that are immediately exercisable or will be immediately exercisable within 60 days of December 31, 2023.

 

 

 

 

CUSIP No. 45674E 109 Page 3 of 4 Pages

 

Item 1(a) Name of Issuer 

 

IN8bio, Inc., a Delaware corporation (the “Issuer”)

 

Item 1(b) Address of Issuer’s Principal Executive Offices 

 

350 5th Avenue, Suite 5330

New York, NY 10118

 

Item 2(a) Name of Person Filing 

 

This Schedule 13G is filed by William Tai-Wei Ho (the “Reporting Person”).

 

Item 2(b) Address of Principal Business Office or, if none, Residence 

 

c/o IN8bio, Inc.

350 5th Avenue, Suite 5330

New York, NY 10118

 

Item 2(c) Citizenship 

 

United States of America

 

Item 2(d) Title of Class of Securities 

 

Common Stock, $0.0001 par value per share

 

Item 2(e) CUSIP Number 

 

45674E 109

 

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a 

 

Not applicable.

 

Item 4 Ownership 

 

(a) Amount beneficially owned: See responses to Item 9 on the attached cover page.

 

(b) Percent of class: See responses to Item 11 on the attached cover page.

 

(c) Number of shares as to which the person has:

 

  (i) Sole power to direct the vote: See responses to Item 5 on the attached cover page.
  (ii) Shared power to direct the vote: See responses to Item 6 on the attached cover page.
  (iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on the attached cover page.
  (iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on the attached cover page.

 

Item 5 Ownership of Five Percent or Less of a Class 

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

 

Item 6 Ownership of More than Five Percent of Another Person 

 

Not applicable.

 

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company 

 

Not applicable.

 

Item 8 Identification and Classification of Members of the Group 

 

Not applicable.

 

Item 9 Notice of Dissolution of Group 

 

Not applicable.

 

Item 10 Certification 

 

Not applicable.

 

 

 

 

CUSIP No. 45674E 109 Page 4 of 4 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 13, 2024

 

WILLIAM TAI-WEI HO

 

/s/ William Tai-Wei Ho

 
Signature